semaglutide phase 1 slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy Novo Nordisk's semaglutide shows promise

They identified a protein called Med14 part of a larger protein complex called Mediator that was enabling the GLP-1-dependent changes in gene expression that lead to pancreatic health benefits

The patients ended the trial at a healthier ratio

This represents a fundamentally new type of addiction treatment, one that sidesteps the dopamine-focused methods that have dominated the field

11 Whole brain cFos expression in response to semaglutide, MK-801, GLP-1 and GLP-1MK-801

These peptides, identified through bioinformatic analyses and molecular docking, show promise due to their structural activity relationships and interaction mechanisms